American specialty pharmaceutical company Cumberland Pharmaceuticals has announced that its potent antibiotic Vibativ (telavancin) has been added to a national group purchasing agreement with Premier, a leading US healthcare improvement company.

Effective October 1, 2025, the agreement allows Premier’s network of approximately 4,350 hospitals and 325,000 providers to access special pricing and terms pre-negotiated for Vibativ, available in both the 12-vial carton and the newly introduced 4-vial Starter Pak.

The expanded access gives healthcare providers greater flexibility in ordering Vibativ, supporting both inpatient and outpatient settings. While the 12-vial carton remains the standard packaging for institutions managing higher patient volumes, the 4-vial Starter Pak provides a cost-effective option designed to help hospitals and clinicians initiate therapy and manage their inventory more effectively.

"We're pleased to expand the availability of Vibativ through Premier's extensive network, giving thousands of hospitals and providers access to the product's standard carton and the new Starter Pak. This product addition underscores our commitment to delivering flexible, cost-effective solutions to support clinicians in treating difficult-to-treat Gram-positive infections,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.

Vibativ is a once-daily, dual mechanism antibiotic that has proven effective against a broad range of serious Gram-positive bacterial infections. It is indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus (including methicillin-resistant strains) and complicated skin and skin structure infections (cSSSI).

Headquartered in Tennessee, Cumberland Pharmaceuticals develops, acquires, and commercialises products for the hospital acute care, gastroenterology and oncology market segments.